Trial · NCT04599816
Levosimendan Administration in Pulmonary Hypertension
NCT04599816, Not applicable, Completed, Aretaieion University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Levosimendan Administration in Pulmonary Hypertension. Trials, record NCT04599816. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04599816
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Levosimendan Administration in Pulmonary Hypertension
- NCT number
- NCT04599816
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 45 participants, actual
- Lead sponsor
- Aretaieion University Hospital
- Conditions
- Hypertension, Pulmonary, Cardiac Failure, Pulmonary Vascular Resistance Abnormality
- Interventions
- levosimendan at a dose of 3 mcg/kg, levosimendan at a dose of 6 mcg/kg, levosimendan at a dose of 12 mcg/kg
- First posted
- 2020-10-23
- Last updated
- 2023-02-08
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | change from baseline in mean pulmonary arterial pressure (MPAP) | 20 minutes after levosimendan administration, at the end of surgery and 2 hours after Intensive Care Unit (ICU) admission | a Swan-Ganz catheter will be used for hemodynamic measurements |
| Secondary | change from baseline in pulmonary vascular resistance (PVR) | 20 minutes after levosimendan administration, at the end of surgery and 2 hours after Intensive Care Unit (ICU) admission | a Swan-Ganz catheter will be used for hemodynamic measurements |
| Secondary | change from baseline in mean arterial pressure (MAP) | 20 minutes after levosimendan administration, at the end of surgery and 2 hours after Intensive Care Unit (ICU) admission | a Swan-Ganz catheter will be used for hemodynamic measurements |
| Secondary | change from baseline in systemic vascular resistance (SVR) | 20 minutes after levosimendan administration, at the end of surgery and 2 hours after Intensive Care Unit (ICU) admission | a Swan-Ganz catheter will be used for hemodynamic measurements |
| Secondary | change from baseline in pulmonary capillary wedge pressure (PCWP) | 20 minutes after levosimendan administration, at the end of surgery and 2 hours after Intensive Care Unit (ICU) admission | a Swan-Ganz catheter will be used for hemodynamic measurements |
| Secondary | change from baseline in cardiac output (CO) | 20 minutes after levosimendan administration, at the end of surgery and 2 hours after Intensive Care Unit (ICU) admission | a Swan-Ganz catheter will be used for hemodynamic measurements |
| Secondary | change from baseline in tricuspid annular plane systolic excursion (TAPSE) | 20 minutes after levosimendan administration, at the end of surgery, 2 hours after Intensive Care Unit (ICU) admission and 80 hours after levosimendan administration | transthoracic and transesophageal echocardiography will be used for echocardiographic measurements |
| Secondary | change from baseline in fractional area change | 20 minutes after levosimendan administration, at the end of surgery, 2 hours after Intensive Care Unit (ICU) admission and 80 hours after levosimendan administration | transthoracic and transesophageal echocardiography will be used for echocardiographic measurements |
| Other | change from baseline in blood levels of levosimendan | 20 minutes, 6 hours, 12 hours, 24 hours and 80 hours after administration | blood levels will be measured with liquid chromatography |
| Other | change from baseline in blood levels of interleukin-6 (IL-6) | end of surgery, 6 hours, 12 hours and 24 hours after Intensive Care Unit (ICU) admission | blood levels will be measured with the enzyme linked immunosorbent assay (ELISA) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04599816
GET https://conductscience.org/api/trials/v1/NCT04599816/registered